Delving into the Latest Updates on Yantai Chuanghe Biotechnology Co., Ltd with Synapse

Overview

Basic Info

Introduction

Yantai Chuanghe Biotechnology Co., Ltd. was established on the 28th of December, 2021. The company's registration is located on Changning Road, Binhai Street, Laishan District, in the city of Yantai, Shandong Province.

Tags

Urogenital Diseases

Neoplasms

Endocrinology and Metabolic Disease

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Neoplasms	2
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Small molecule drug	2

Primary objective: To preliminarily evaluate the effectiveness of different doses of LY01021 during controlled ovarian stimulation in female subjects undergoing assisted reproductive technology. Secondary objective: To preliminarily evaluate the safety of different doses of LY01021 during controlled ovarian stimulation in female subjects undergoing assisted reproductive technology.

Start Date09 Oct 2024

Sponsor / Collaborator

Yantai Chuanghe Biotechnology Co., Ltd

CTR20241485

/ CompletedPhase 1

在健康女性受试者中评价食物对LY01021药代动力学特征影响的随机、开放、单次给药、两周期、双交叉设计的I期临床研究

[Translation] A randomized, open-label, single-dose, two-period, double-crossover phase I clinical study to evaluate the effect of food on the pharmacokinetic characteristics of LY01021 in healthy female subjects

评价食物对健康女性受试者单次口服LY01021 80 mg药代动力学特征的影响。

[Translation]

To evaluate the effect of food on the pharmacokinetic characteristics of LY01021 80 mg after a single oral dose in healthy female subjects.

Start Date15 May 2024

Sponsor / Collaborator

Yantai Chuanghe Biotechnology Co., Ltd

CTR20234302

/ RecruitingPhase 1

评价LPM6690176胶囊在晚期恶性实体瘤患者中的安全耐受性、药代动力学特征和初步疗效的非随机、开放、I期临床研究

[Translation] A non-randomized, open-label, phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of LPM6690176 capsules in patients with advanced malignant solid tumors

评价LPM6690176胶囊在晚期恶性实体瘤患者中的安全耐受性，观察剂量限制性毒性（DLT），确定最大耐受剂量（MTD）；评价LPM6690176胶囊在晚期恶性实体瘤患者中的药代动力学（PK）特征和初步疗效；

[Translation]

To evaluate the safety and tolerability of LPM6690176 capsules in patients with advanced malignant solid tumors, observe dose-limiting toxicity (DLT), and determine the maximum tolerated dose (MTD); to evaluate the pharmacokinetic (PK) characteristics and preliminary efficacy of LPM6690176 capsules in patients with advanced malignant solid tumors;

Start Date27 Feb 2024

Sponsor / Collaborator

Yantai Chuanghe Biotechnology Co., Ltd

100 Clinical Results associated with Yantai Chuanghe Biotechnology Co., Ltd

Login to view more data

0 Patents (Medical) associated with Yantai Chuanghe Biotechnology Co., Ltd

Login to view more data

100 Deals associated with Yantai Chuanghe Biotechnology Co., Ltd

Login to view more data

100 Translational Medicine associated with Yantai Chuanghe Biotechnology Co., Ltd

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 15 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Phase 2 Clinical

Login to view more data